Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Blood. 2022 Dec 22;140(25):2754-2756. doi: 10.1182/blood.2022016963.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Cytarabine
  • Follow-Up Studies
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / etiology

Substances

  • Cytarabine